Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etidronate for brain calcification in Fahr's disease
2022-003299-17Phase 2Active
- Sponsor
- University Medical Center Utrecht
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in idiopathic basal ganglia calcification (PFBC) comparing Etidronate with Placebo (2 arms). Primary endpoint: Change in cognitive functioning. Started Jan 2023; status: active.
02
Drugs
etidronate
03
Conditions
idiopathic basal ganglia calcification (PFBC)
Beyond the preview
Go deeper on 2022-003299-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003299-17.